
Allogeneic hematopoietic stem cell transplantation (HSCT) has represented for long the only established cure for thalassemia and sickle cell disease. With the recent approval of gene therapy products, the therapeutic algorithm for hemoglobinopathies is being reshaped, raising questions about patient selection, donor availability, and long-term outcomes.
The introductory talk will review current indications for allogeneic HSCT, summarize outcomes from matched and alternative donor transplants, and outline how the field is adapting to a more crowded therapeutic landscape.
The two main talks will then focus on the haploidentical transplantation and on the two major platforms: αβ T-cell depleted haploidentical transplant and PTCy-based haploidentical transplant — as strategies to overcome the persistent barrier of donor availability.
Date: 03 December 2026
Time: 13:00 CET丨07:00 EST丨20:00 CST Asia
Webinar ID: 840 0222 5348
Webinar Secretariat: journal.webinar@mdpi.com

Hematology and Bone Marrow Unit, Hospital University of Parma, Parma, Italy;Dr. Prezioso is an Italian hematologist based in Parma, specializing in bone marrow/stem cell transplantation, particularly T-depleted allogeneic and haploidentical transplantation, with a strong parallel research background in cardiac stem cell biology and infectious complications in hematological malignancies. Education: Degree in Medicine, University of Parma (2005); Specialization in Internal Medicine (2010); PhD in Systemic Physiopathology (cardiac and bone marrow stem cells, regenerative medicine), University of Parma (2014). Career highlights: • Transplant Program Director (CIC 245) since 2024. • Head of the BMT Unit of Parma since September 2023. • Head of Clinical Unit (CIC 245) since 2019, and Head of the Bone Marrow Collection Unit (CIC 245) since 2016. • Physician in the Bone Marrow and Hematology Unit, Parma, since 2011, focused mainly on T-depleted allogeneic transplantation. • Regional delegate for GITMO (Gruppo Italiano Midollo Osseo), 2023–2025. Research & publications: Contributor to well over 60 peer-reviewed publications, spanning haploidentical stem cell transplantation, GVHD, infectious complications (SEIFEM and EPICOVIDEHA collaborative studies), COVID-19 in hematological malignancy patients, and earlier work on cardiac progenitor cells and cardiotoxicity. Conferences: Extensive and continuous participation in EBMT, ASH, EHA, GITMO, and SEIFEM annual meetings from 2009 to 2026, including a role as Scientific Secretariat for the 8th International Symposium on Haploidentical Stem Cell Transplantation.
This is a FREE webinar. After registering, you will receive a confirmation email containing information on how to join the webinar. Registrations with academic institutional email addresses will be prioritized.
Certificates of attendance will be delivered to those who attend the live webinar.
Can’t attend? Register anyway and we’ll let you know when the recording is available to watch.
|
Speaker |
Presentation Title |
Time in CET |
Time in EST |
Time in CST Asia |
|
Dr. Lucia Prezioso |
Chair Introduction |
13:00-13:10 |
07:00–07:10 |
20:00-20:10 |
|
Dr. Lucia Prezioso |
Hemoglobinopathies: Where Do We Stand |
13:10-13:30 |
07:10–07:30 |
20:10–20:30 |
|
Dr. Pietro Sodani |
T-cell Depleted Approaches: Precision in Graft Engineering |
13:30-13:50 |
07:30–07:50 |
20:30–20:50 |
|
Dr. Lawrence Faulkner |
PTCy-Based Platforms: Widening Access to Cure |
13:50-14:10 |
07:50–08:10 |
20:50–21:10 |
|
|
Q&A Session |
14:10-14:25 |
08:10–08:25 |
21:10–21:25 |
|
Dr. Lucia Prezioso |
Closing of Webinar |
14:25-14:30 |
08:25–08:30 |
21:25–21:30 |
Internal Medicine Department, Santa Croce Hospital, Fano, Italy;Dr. Sodani is an Italian haematologist with over 30 years of clinical and research experience, specializing in bone marrow transplantation, thalassemia, and sickle cell disease. Education: Medical degree from the University of Perugia (1993) and a PhD in Haematology (1998). Career highlights:. • Served as Scientific Consultant at Charité Hospital, Berlin (Haemato-Oncology Pediatric Section, Bone Marrow Transplant Unit), 2019–2022. • Haematologist at San Camillo Hospital, Rome (2015–2017). • Extensive tenure (2004–2015) at the Mediterranean Haematology Foundation / Tor Vergata University Policlinic, Rome, focused on bone marrow transplantation for thalassemia and sickle cell disease — treating roughly 180 thalassemic patients and helping develop transplant protocols (including haploidentical transplantation approaches) to improve outcomes and expand the donor pool for patients without HLA-matched relatives. • Earlier roles include Consultant Haematologist at Hospital S. Salvatore, Pesaro (1999–2004, ~80 transplants/year), and training under Prof. Massimo Martelli at the University Hospital of Perugia (1993–1998). • International experience includes a placement at the Royal Children's Hospital, Bristol, UK (1997). Research & publications: Author/co-author of over 30 peer-reviewed publications, primarily on haploidentical stem cell transplantation, thalassemia, and sickle cell disease treatment outcomes. Volunteer work: Active in humanitarian medical work, including thalassemia treatment programs in Pakistan (Cure2Children Foundation) and co-founding the CureThalassemia Foundation, working with Narayana Hospital in Bangalore, India.
Medical Coordinator, Cure2Children Foundation, Florence, Italy;Dr. Faulkner is an internationally recognized pediatric hematologist-oncologist with over 30 years of experience in bone marrow transplantation, with a particular focus on hemoglobinopathies (thalassemia and sickle cell disease) in low- and middle-income countries. Education: Medical degree from the University of Florence, Italy (1983, cum laude); pediatric residency at Long Island College Hospital, Brooklyn (1986–89); Pediatric Hematology-Oncology fellowship at Memorial Sloan Kettering Cancer Center/New York Hospital/Cornell (1989–92). Career highlights: • Medical Coordinator of the Cure2Children Foundation (Florence, Italy) since 2006, which he also founded. • Pediatric Hematology-Oncology attending at the Children's Hospital of Florence (Ospedale Meyer), 1994–2005, and earlier at Policlinico Gemelli, Rome (1992–93). • Program Director, Sankalp-People Tree Hospitals Bone Marrow Transplant Unit, Bangalore, India (2015–17), and Medical Coordinator of the Sankalp India Foundation since 2017. • Consultant for DKMS Group Germany's Access to Transplant program since 2020. • Visiting professor at Yerevan State Medical University, Armenia. Memberships & roles: Member of EBMT, ASH, ASCO, and SIOP; Chair of the Outreach Subcommittee (Pediatric Diseases Working Party, EBMT); JACIE inspector; Leader of the Thalassemia Group at Cure4Kids (St Jude). Research & funding: Principal investigator or coordinator on numerous grants (totaling several million euros) supporting thalassemia treatment and prevention programs in Pakistan, India, and globally, plus neuroblastoma research initiatives. Author of over 60 peer-reviewed publications spanning bone marrow transplantation, hemoglobinopathies, and pediatric oncology. Recognition: 2021 Distinguished Service Award from CIBMTR; featured in a dedicated chapter of Nobel laureate Muhammad Yunus's book Building Social Business. Editorial board member for Annals of Hematology and Thalassemia Reports.
Hematopoietic Stem Cell Transplantation: Current Research and New Perspectives
Edited by Lucia Prezioso
Deadline for manuscript submissions: 20 November 2026